Campfieldtx
2 known investors
cAMPfield is a clinical-stage biopharmaceutical company developing prifemilast, a once-daily oral PDE4B-selective inhibitor for immune-mediated inflammatory diseases, primarily inflammatory bowel disease (ulcerative colitis and Crohn's disease). The company is advancing the drug into global Phase 2 clinical development.
Founders & leadership
Investors · 2
Frequently asked questions
- What does Campfieldtx do?
- cAMPfield is a clinical-stage biopharmaceutical company developing prifemilast, a once-daily oral PDE4B-selective inhibitor for immune-mediated inflammatory diseases, primarily inflammatory bowel disease (ulcerative colitis and Crohn's disease). The company is advancing the drug into global Phase 2 clinical development.
- Who are Campfieldtx's investors?
- Campfieldtx's investors include Frazier Life Sciences, Longitude Capital.